Skip to content
Open access

Characterization of Full‐Length Antibody Complexes Through HDX‐Mass Spectrometry Coupled With NMR Spectroscopy: New Insight Into Avelumab/PD‐L1 Interaction

Aug 2026 · Angewandte Chemie · Vol 65 · 0 citations · 90 references
Medicine

TL;DR

An integration of solid‐state nuclear magnetic resonance (SSNMR) and hydrogen–deuterium exchange mass spectrometry (HDX‐MS) is introduced to explore the interaction between Avelumab and the programmed cell death‐ligand 1 (PD‐L1).

Abstract

ABSTRACT Recombinant biomacromolecules have significantly transformed pharmaceuticals, in particular monoclonal antibodies (mAbs) that target key areas in oncology, immunology, inflammation, and neurodegenerative diseases. Developing biotherapeutics requires a detailed understanding of their biological properties. This, in turn, brings about the importance of characterizing higher‐order protein structures at each stage, from production to patient. The flexibility and size of the mAbs often prevent achieving atomic‐level structural information in the pharmaceutical formulation by traditional methods. In this study, we introduce an integration of solid‐state nuclear magnetic resonance (SSNMR) and hydrogen–deuterium exchange mass spectrometry (HDX‐MS) to explore the interaction between Avelumab and the programmed cell death‐ligand 1 (PD‐L1). With this approach, we were able to obtain epitope (by both NMR and HDX) and paratope mapping (by HDX), together with a detailed characterization of the structural rearrangements arising upon binding. This methodology provides both mechanistic and structural insights important for the design and optimization of biotherapeutics.

Read PDF

Similar papers

Open access Oct 2026

Fast Intrinsic NMR Reporters of Molecular Changes Correlating with Biological Activity in Stressed Therapeutic Monoclonal Antibodies

The biological activity and stability of monoclonal antibodies (mAbs) can be potentially compromised by chemical and conformational changes and assessing the structural integrity of mAbs is therefore a critical task in biopharmaceutical development. Monitoring higher-order structure (HOS) in formulated mAbs remains a...

M. Gairí, M. González, Victor A. Beaumont et al. · 0 citations
Open access Sep 2026

Backbone-matched comparison of two trastuzumab-based antibody–drug conjugates: payload localization and gas-phase heterogeneity of trastuzumab deruxtecan and trastuzumab rezetecan

Antibody–drug conjugates (ADCs) are biotherapeutics that are structurally heterogeneous due to the way each ADC is formed. Therefore, complementary analytical approaches need to be used in order to achieve a complete characterization of all aspects of the structure of these biotherapeutics. This project created a multi...

HeeJae Yoo, Abhik Mojumdar, Minsun Kim et al. · 0 citations
Open access Oct 2026

Structural Basis for the Rational Design of UAMC-1110-Based FAP Radiopharmaceuticals

Radioligands targeting fibroblast activation protein alpha (FAP) are promising tools for cancer diagnosis and therapy. However, the molecular binding mode of clinically established UAMC-1110-derived ligands such as FAPI-46 remains insufficiently characterized. To simplify synthesis while preserving key binding properti...

Chao Zhang, J. Gerhards, Lara Scharbert et al. · 0 citations
Sep 2026

Multimodal Dynamic NMR‐Based Elucidation of Binding and Rotational Mobility of Fluorinated Anticancer Drugs in POPC Large Unilamellar Vesicles

Understanding the interactions between fluorinated anticancer drugs (FACDs) and lipid assemblies is fundamental to the development of next‐generation therapeutics with improved efficacy and pharmacological safety. To this end, atomistic‐level interactions, in terms of binding and dynamics of FACDs, such as 5‐fluoro...

Jyothirmai Pujari, B. V. N. Phani Kumar · 0 citations
Review Open access Sep 2026

Smaller is better: nanobodies meet NMR.

This review summarizes recent advances in nanobody engineering for NMR studies, including the synthetic nanobodies, highlights the nanobodies' role in overcoming size and stability limitations, and discusses future directions for integrating nanobodies into emerging NMR methodologies, with an emphasis on protein dynami...

Oleg Y. Dmitriev · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.